CN1507442A - 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 - Google Patents
激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 Download PDFInfo
- Publication number
- CN1507442A CN1507442A CNA028096940A CN02809694A CN1507442A CN 1507442 A CN1507442 A CN 1507442A CN A028096940 A CNA028096940 A CN A028096940A CN 02809694 A CN02809694 A CN 02809694A CN 1507442 A CN1507442 A CN 1507442A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- trifluoromethyl
- acetate
- furyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0111523.7 | 2001-05-11 | ||
| GBGB0111523.7A GB0111523D0 (en) | 2001-05-11 | 2001-05-11 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1507442A true CN1507442A (zh) | 2004-06-23 |
Family
ID=9914442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028096940A Pending CN1507442A (zh) | 2001-05-11 | 2002-05-09 | 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7091237B2 (https=) |
| EP (1) | EP1392674B1 (https=) |
| JP (1) | JP2004534035A (https=) |
| KR (1) | KR20040023600A (https=) |
| CN (1) | CN1507442A (https=) |
| AT (1) | ATE301649T1 (https=) |
| BR (1) | BR0209468A (https=) |
| CA (1) | CA2446797A1 (https=) |
| CO (1) | CO5540343A2 (https=) |
| CZ (1) | CZ20033064A3 (https=) |
| DE (1) | DE60205481T2 (https=) |
| ES (1) | ES2247322T3 (https=) |
| GB (1) | GB0111523D0 (https=) |
| HU (1) | HUP0304051A3 (https=) |
| IL (1) | IL158332A0 (https=) |
| MX (1) | MXPA03010285A (https=) |
| NO (1) | NO20034986L (https=) |
| PL (1) | PL367478A1 (https=) |
| WO (1) | WO2002092590A1 (https=) |
| ZA (1) | ZA200308352B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0113232D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical process |
| BRPI0211844B8 (pt) | 2001-08-10 | 2021-05-25 | Nippon Chemiphar Co | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica |
| ITRM20020014A1 (it) * | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| JP2005035966A (ja) * | 2002-09-06 | 2005-02-10 | Takeda Chem Ind Ltd | フランまたはチオフェン誘導体およびその医薬用途 |
| AU2003261935A1 (en) * | 2002-09-06 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| AU2003296402A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Thiophene derivative ppar modulators |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| AU2004291262C1 (en) | 2003-11-05 | 2011-08-11 | F. Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| BRPI0609178A2 (pt) * | 2005-02-28 | 2016-08-23 | Nippon Chemiphar Co | composto ou um sal do mesmo, e, ativador para o receptor ativado do proliferador de peroxissoma delta |
| CN101193876B (zh) * | 2005-05-07 | 2011-05-11 | 财团法人首尔大学校产学协力财团 | 制备PPARδ的配体的方法和用于制备该配体的中间化合物 |
| KR20080014075A (ko) * | 2005-05-25 | 2008-02-13 | 닛뽕 케미파 가부시키가이샤 | 페록시좀 증식제 활성화 수용체의 활성화제 |
| SI1931660T1 (sl) | 2005-09-29 | 2012-12-31 | Sanofi | Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| JP2009523132A (ja) * | 2006-01-10 | 2009-06-18 | スミスクライン ビーチャム コーポレーション | ｛２−メチル−４−［４−メチル−２−（４−トリフルオロメチルフェニル）チアゾール−５−イルメチルチオ］フェノキシ｝−酢酸の多形体形態 |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| PL2074093T3 (pl) * | 2006-08-22 | 2013-03-29 | Sun Pharmaceutical Ind Ltd | Sposób przygotowywania inhibitorów metaloproteinazy macierzy i chiralnego środka wspomagającego |
| US20080187928A1 (en) | 2006-12-29 | 2008-08-07 | The Salk Institute For Biological Studies | Methods for enhancing exercise performance |
| FR2910894A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation. |
| EA200970793A1 (ru) * | 2007-02-23 | 2010-02-26 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом |
| KR20080082541A (ko) * | 2007-03-07 | 2008-09-11 | 동아제약주식회사 | 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도 |
| DE102008007400A1 (de) * | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
| EP2277874B1 (en) | 2008-04-15 | 2018-06-27 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
| CN101643451B (zh) | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| EP2612669A4 (en) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST |
| EP2970161B8 (en) * | 2013-03-14 | 2018-10-17 | Janssen Pharmaceutica NV | Gpr120 agonists for the treatment of type ii diabetes |
| US9249133B2 (en) * | 2013-03-14 | 2016-02-02 | Dow Agrosciences Llc | Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
-
2001
- 2001-05-11 GB GBGB0111523.7A patent/GB0111523D0/en not_active Ceased
-
2002
- 2002-05-09 EP EP02722506A patent/EP1392674B1/en not_active Expired - Lifetime
- 2002-05-09 MX MXPA03010285A patent/MXPA03010285A/es unknown
- 2002-05-09 HU HU0304051A patent/HUP0304051A3/hu unknown
- 2002-05-09 AT AT02722506T patent/ATE301649T1/de not_active IP Right Cessation
- 2002-05-09 CN CNA028096940A patent/CN1507442A/zh active Pending
- 2002-05-09 JP JP2002589475A patent/JP2004534035A/ja active Pending
- 2002-05-09 US US10/476,194 patent/US7091237B2/en not_active Expired - Fee Related
- 2002-05-09 ES ES02722506T patent/ES2247322T3/es not_active Expired - Lifetime
- 2002-05-09 DE DE60205481T patent/DE60205481T2/de not_active Expired - Fee Related
- 2002-05-09 IL IL15833202A patent/IL158332A0/xx unknown
- 2002-05-09 WO PCT/GB2002/002152 patent/WO2002092590A1/en not_active Ceased
- 2002-05-09 BR BR0209468-1A patent/BR0209468A/pt not_active IP Right Cessation
- 2002-05-09 CZ CZ20033064A patent/CZ20033064A3/cs unknown
- 2002-05-09 KR KR10-2003-7014660A patent/KR20040023600A/ko not_active Withdrawn
- 2002-05-09 PL PL02367478A patent/PL367478A1/xx not_active Application Discontinuation
- 2002-05-09 CA CA002446797A patent/CA2446797A1/en not_active Abandoned
-
2003
- 2003-10-27 ZA ZA200308352A patent/ZA200308352B/en unknown
- 2003-11-10 NO NO20034986A patent/NO20034986L/no not_active Application Discontinuation
- 2003-11-10 CO CO03099078A patent/CO5540343A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040157890A1 (en) | 2004-08-12 |
| ZA200308352B (en) | 2005-01-27 |
| WO2002092590A1 (en) | 2002-11-21 |
| DE60205481T2 (de) | 2006-05-24 |
| HUP0304051A3 (en) | 2005-11-28 |
| NO20034986D0 (no) | 2003-11-10 |
| CA2446797A1 (en) | 2002-11-21 |
| IL158332A0 (en) | 2004-05-12 |
| EP1392674B1 (en) | 2005-08-10 |
| ATE301649T1 (de) | 2005-08-15 |
| NO20034986L (no) | 2003-11-10 |
| JP2004534035A (ja) | 2004-11-11 |
| CZ20033064A3 (cs) | 2004-02-18 |
| PL367478A1 (en) | 2005-02-21 |
| CO5540343A2 (es) | 2005-07-29 |
| GB0111523D0 (en) | 2001-07-04 |
| KR20040023600A (ko) | 2004-03-18 |
| US7091237B2 (en) | 2006-08-15 |
| DE60205481D1 (de) | 2005-09-15 |
| ES2247322T3 (es) | 2006-03-01 |
| EP1392674A1 (en) | 2004-03-03 |
| MXPA03010285A (es) | 2004-03-09 |
| BR0209468A (pt) | 2004-08-03 |
| HUP0304051A2 (hu) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1507442A (zh) | 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 | |
| CN1164579C (zh) | 噻唑和噁唑衍生物以及它们的药物应用 | |
| CN1184215C (zh) | 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物 | |
| CN1252057C (zh) | 用于治疗与paar有关的疾病的噻唑衍生物 | |
| CN1578659A (zh) | 过氧化物酶体增殖剂激活的受体(ppar)的调节剂 | |
| CN1543451A (zh) | 过氧化物酶体增生剂激活的受体的调节剂 | |
| CN1674897A (zh) | 作为hppar激活剂的苯基链烷酸和苯氧基链烷酸衍生物 | |
| JP4234431B2 (ja) | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 | |
| CN1093124C (zh) | 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物 | |
| CN1129576C (zh) | 用作环氧酶－2抑制剂的苯基杂环化合物 | |
| CN1066441C (zh) | 异唑基苯基磺酰胺的衍生物及其在制备内皮缩血管肽拮抗药中的应用 | |
| CN1909902A (zh) | 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物 | |
| CN1279026C (zh) | 前列腺素内过氧化物h合酶生物合成抑制剂 | |
| CN1215059C (zh) | 新的杂环化合物及其盐和它们的医药用途 | |
| CN100349856C (zh) | 丙酸衍生物及其作为hPPAR活化剂的用途 | |
| CN1946666A (zh) | 用于治疗代谢性疾病的化合物、药物组合物和方法 | |
| CN1503774A (zh) | 羧酸衍生物及其盐 | |
| CN1308297C (zh) | 氨基磺酸苯基酯衍生物 | |
| CN1509173A (zh) | 用作糖尿病治疗中的PPAR－α和PPAR－γ激活剂的羧酸取代的噁唑衍生物 | |
| CN1649820A (zh) | 调节ppar活性的化合物及其制备方法 | |
| CN1794989A (zh) | 用于治疗糖尿病的n－(((((1,3－噻唑－2－基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物 | |
| CN1529698A (zh) | 用于治疗心血管及有关疾病的噻唑或噁唑衍生物 | |
| CN1767823A (zh) | 哮喘和过敏性炎症调节剂 | |
| CN1751037A (zh) | 作为ppar调节剂的磺酰胺衍生物 | |
| CN1226555A (zh) | 抗真菌剂及其制备方法和中间体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |